

Cite this: *Chem. Sci.*, 2020, 11, 11435

All publication charges for this article have been paid for by the Royal Society of Chemistry

# Enhancing the photodynamic therapy efficacy of black phosphorus nanosheets by covalently grafting fullerene C<sub>60</sub>†

Yajuan Liu,<sup>‡a</sup> Daoming Zhu,<sup>‡b</sup> Xianjun Zhu,<sup>a</sup> Gaoke Cai,<sup>c</sup> Jianhua Wu,<sup>a</sup> Muqing Chen,<sup>‡a</sup> Pingwu Du,<sup>‡a</sup> Yongshun Chen,<sup>\*c</sup> Wei Liu<sup>‡\*b</sup> and Shangfeng Yang<sup>‡\*a</sup>

Few-layer black phosphorus (BP) nanosheets show potential application in biomedicine such as photodynamic therapy (PDT), and are therefore commonly used in anticancer therapy and nanomedicine due to being relatively less invasive. However, they suffer from low ambient stability and poor therapeutic efficacy. Herein, C<sub>60</sub> was covalently grafted onto the edges of BP nanosheets, and the resultant BP-C<sub>60</sub> hybrid was applied as a novel endocytosing photosensitizer, resulting in not only significantly enhanced PDT efficacy relative to that of the pristine BP nanosheets, but also drastically improved stability in a physiological environment, as confirmed by both *in vitro* and *in vivo* studies. Such improved stability was due to shielding effect of the stable hydrophobic C<sub>60</sub> molecules. The enhanced PDT efficacy is interpreted from the photoinduced electron transfer from BP to C<sub>60</sub>, leading to the promoted generation of <sup>•</sup>OH radicals, acting as a reactive oxygen species (ROS) that is effective in killing tumor cells. Furthermore, the BP-C<sub>60</sub> hybrid exhibited low systemic toxicity in the major organs of mice. The BP-C<sub>60</sub> hybrid represents the first BP-fullerene hybrid nanomaterial fulfilling promoted ROS generation and consequently enhanced PDT efficacy.

Received 16th June 2020  
Accepted 7th September 2020

DOI: 10.1039/d0sc03349a

rsc.li/chemical-science

## Introduction

Developing effective tumor therapies is of considerable importance due to the increased incidence of malignant tumors over recent years.<sup>1</sup> Photodynamic therapy (PDT) is a modern technique of tumor therapy and is relatively less invasive with low systemic toxicity. PDT can induce vascular damage in the tumor and activate an immune system response, and is thus commonly used in anticancer therapy and nanomedicines.<sup>2–4</sup> The principle of PDT is based on a series of photochemical reactions triggered by a photosensitizer upon light irradiation. Excitation of the photosensitizer results in energy transfer to surrounding oxygen molecules, which generate cytotoxic reactive oxygen species (ROS) capable of killing cancer cells.<sup>2–4</sup> A photosensitizer essentially

determines the absorption efficiency and depth of light penetration and is thus decisive for PDT efficacy.<sup>5</sup>

As an emerging two-dimensional (2D) layered semiconductor, few-layer black phosphorus (BP) nanosheets have recently been utilized as a novel photosensitizer in PDT.<sup>6–15</sup> BP exhibits a thickness-dependent band gap over the range of 0.3 eV for bulk materials to 2.0 eV for monolayers, resulting in tunable and broad optical absorption across the UV to visible range.<sup>6–9</sup> This along with the high charge carrier mobility of  $\sim 1000 \text{ cm}^2 \text{ V}^{-1} \text{ s}^{-1}$  enables BP to be used in diverse potential applications, such as transistors, biomedicines, and in energy conversion and storage.<sup>6–12</sup> Various biomedical applications of BP, such as in photodynamic and photothermal cancer therapy and *in vivo* photoacoustic imaging, and a drug delivery platform and multi-functional theranostic agents for cancer treatment, have been reported in recent years.<sup>10–12</sup> In particular, in 2015 Xie *et al.* first demonstrated the ability and the capability of BP nanosheets in efficient generation of singlet oxygen (<sup>1</sup>O<sub>2</sub>) radicals and consequently utilized BP nanosheets as effective photosensitizers in PDT.<sup>13</sup> This seminal work stimulates further studies of BP nanosheets in PDT, with singlet oxygen (<sup>1</sup>O<sub>2</sub>) radicals typically proposed as the principal reactive oxygen species (ROS) responsible for killing cancer cells.<sup>14–16</sup> However, the reported therapeutic efficacies of BP nanosheets are generally poor and BP nanosheets suffer from low ambient stability, limiting their extensive PDT applications. The low ambient stability of BP nanosheets is due to the existence of a lone pair of electrons in each phosphorus atom,

<sup>a</sup>Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Materials for Energy Conversion, Anhui Laboratory of Advanced Photon Science and Technology, Department of Materials Science and Engineering, University of Science and Technology of China, Hefei 230026, China. E-mail: sfyang@ustc.edu.cn

<sup>b</sup>Key Laboratory of Artificial Micro- and Nano-Structures of Ministry of Education, School of Physics and Technology, Wuhan University, Wuhan 430072, China. E-mail: wliu@whu.edu.cn

<sup>c</sup>Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan 430072, China. E-mail: yongshun2007@163.com

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0sc03349a

‡ These authors contributed equally to this work.






Fig. 1 (a) Schematic illustration of the preparation process of the BP-C<sub>60</sub> hybrid. (b) Application of the BP-C<sub>60</sub> hybrid as a novel endocytosing photosensitizer for PDT.

able to readily react with oxygen adsorbed on the surface of BP nanosheets, leading to facile oxidation.<sup>17–19</sup> Hence, a prerequisite for realizing PDT application of BP nanosheets is to improve their ambient stability. So far a few methods have been developed to improve the ambient stability of BP nanosheets.<sup>20–25</sup> Among them, covalent functionalizations have been demonstrated to one of the most effective approaches in improving the ambient stability of BP nanosheets because the phosphorus atom bearing a lone electron pair can bond directly with another atom, such as carbon and can thus be passivated.<sup>20,21</sup> For example, we recently succeeded in edge-selectively functionalizing BP nanosheets by grafting stable C<sub>60</sub> molecules *via* covalent P–C bonds.<sup>26</sup> Owing to the high stability of hydrophobic C<sub>60</sub> against light, oxygen and water, C<sub>60</sub> molecules within the BP-C<sub>60</sub> hybrid can act as a shield that effectively protects BP nanosheets from oxidation, resulting in significantly improved stability of BP nanosheets in water.<sup>26</sup> An open question is whether C<sub>60</sub> grafting can improve the physiological stability of BP nanosheets in other electrolyte solutions also. Furthermore, given that fullerenes have also been used in PDT,<sup>27,28</sup> it is intriguing to investigate whether C<sub>60</sub> grafting affects the PDT efficacy of BP nanosheets.

Herein, we applied a BP-C<sub>60</sub> hybrid as a novel endocytosed photosensitizer (Fig. 1), resulting in not only significantly enhanced PDT efficacy relative to that of the pristine BP nanosheets, but also drastic improvement of its physiological stability in serum, phosphate buffered saline (PBS) and water as confirmed by both *in vitro* and *in vivo* studies. On the basis of mechanistic studies, we revealed that the enhanced PDT efficacy is due to the generation of ROS in the form of <sup>•</sup>OH radicals resulting from the photoinduced electron transfer from BP to C<sub>60</sub>. The cytotoxicity of the BP-C<sub>60</sub> hybrid was further evaluated *in vivo* by inspecting the major organs of mice, confirming its low cytotoxicity and negligible side effects.

## Results and discussion

### Synthesis, characterization and physiological stability of the BP-C<sub>60</sub> hybrid

The BP-C<sub>60</sub> hybrid was synthesized by a solid-state mechanochemical method, as reported previously.<sup>26,29,30</sup> Briefly, bulk BP and C<sub>60</sub> powders were mixed in a mass ratio of 1 : 2 and ball-milled within an Ar atmosphere in a planetary ball-milling

machine at 250 rpm for 24 h (Fig. 1a). Unreacted C<sub>60</sub> was removed from the resultant black product by Soxhlet-extraction with CS<sub>2</sub> for 48 h. Grafting of C<sub>60</sub> molecules selectively onto the edges of BP nanosheets *via* covalent P–C bonds was confirmed through a series of spectroscopic and morphological characterization experiments.<sup>26</sup>


The size of nanomaterials is crucial for biological applications, especially *in vivo* experiments. The average size and thickness of the BP-C<sub>60</sub> hybrid are determined by using transmission electron microscopy (TEM) and atomic force microscopy (AFM), respectively. The TEM images indicated that the BP-C<sub>60</sub> hybrid is 100–200 nm in diameter, smaller than that of unmodified BP nanosheets (200–300 nm), which were prepared by ball-milling bulk BP only with LiOH as the additive (abbreviated as BP-BM) (ESI Fig. S1<sup>†</sup>). The decrease in the size of the BP nanosheets is beneficial for their dispersion in aqueous solutions, as required for biomedical applications.<sup>15</sup> AFM analysis indicated that the average thickness of the BP-C<sub>60</sub> hybrid is ~2.5 nm, comparable to that of BP-BM (~2.7 nm), corresponding to a ~4-layer nanosheet, given that the interlayer distance of BP is ~0.52 nm (ESI Fig. S2<sup>†</sup>).<sup>26</sup>

It has been revealed in our previous work that since the grafting ratio of C<sub>60</sub> is not high (the estimated average molar content of C<sub>60</sub> is 19 per 1000 P atoms<sup>26</sup>), C<sub>60</sub> grafting hardly affects the dispersity of BP nanosheets, and the BP-C<sub>60</sub> hybrid has a considerable dispersity in aqueous solutions. Besides, owing to the high stability of hydrophobic C<sub>60</sub> when exposed to light, oxygen or water, grafting of stable C<sub>60</sub> molecules onto the edges of BP nanosheets resulted in improvement of the stability of BP nanosheets in water by a factor of 4.6 after standing for 7 days.<sup>26</sup> To investigate whether such improved stability of BP nanosheets was replicated in other electrolytes used in PDT applications, the stability of the BP-C<sub>60</sub> hybrid dispersion in physiological environments was tested by using fetal bovine serum and phosphate buffered saline (PBS, pH 7.4) for 24 h. According to the comparison of the changes of the optical absorbances of the BP-C<sub>60</sub> hybrid and BP-BM (Fig. 2a–f), the UV-Vis absorbances of the BP-BM dispersions in serum, PBS and water at 460 nm decrease gradually (Fig. 2g–i), with the degradation rate reaching ~10%, 14%, and 33% after standing for 24 h, respectively (ESI Fig. S3<sup>†</sup>). The relatively lower degradation rate of BP-BM in serum is due to the presence of protein and less dissolved oxygen.<sup>5,14</sup> These results reveal the instability of BP nanosheets in aqueous solutions, unfavorable for PDT applications.<sup>21–26</sup> Upon grafting C<sub>60</sub> molecules, the degradation rates of the BP-C<sub>60</sub> hybrid dispersed in serum, PBS and water after standing for 24 h decrease dramatically to ~1.0%, 1.4%, and 1.3%, respectively (ESI Fig. S3<sup>†</sup>). Hence, similar to the case of dispersion in water, grafting of stable C<sub>60</sub> molecules leads to dramatic improvement of the stability of BP nanosheets in serum and PBS as well. This shows the PDT application potential of the BP-C<sub>60</sub> hybrid.

### Intracellular reactive oxygen species (ROS) generation


As we have reported previously, grafting of C<sub>60</sub> molecules onto BP nanosheets was found to result in significantly enhanced





**Fig. 2** Stability of the BP- $C_{60}$  hybrid and BP-BM dispersions in serum, PBS and water. UV vis absorption spectra of the BP- $C_{60}$  hybrid (a–c) and BP-BM (d–f) dispersed in serum (a and d), PBS (b and e) and water (c and f) after standing for 12 and 24 hours. Variation of the absorption ratios ( $A/A_0$ ) at 460 nm of the BP- $C_{60}$  hybrid and BP-BM dispersed in serum (g), PBS (h) and water (i) after standing for 12 and 24 hours.

photocatalytic activity, as demonstrated using degradation of Rhodamine B (RhB) dye and the apparent reaction rate constant increasing by a factor of 8.3.<sup>26</sup> As confirmed in a time-dependent photoluminescence (PL) spectroscopic study, the BP- $C_{60}$  hybrid generated  $\cdot\text{OH}$  radicals during the photocatalytic process (ESI Fig. S4<sup>†</sup>), which may act as a reactive oxygen species (ROS).<sup>31</sup> The presence of ROS at the cellular level was subsequently confirmed using 2,7-dichlorodihydrofluorescein diacetate (DCF) as a probe.<sup>15</sup> For comparison, a comparative sample of  $C_{60}$ -BM was synthesized by ball-milling  $C_{60}$  alone, and an additional control sample consisting of a simple physical mixture of BP and  $C_{60}$  in a ratio of 70% BP-BM and 30%  $C_{60}$  was also synthesized, similar to their respective contents within the BP- $C_{60}$  hybrid.<sup>26</sup> As shown in Fig. 3a, for the BP- $C_{60}$  hybrid, the DCF fluorescence intensity and the number of cells producing ROS are significantly higher than those observed with  $C_{60}$ -BM, BP-BM or the BP/ $C_{60}$ -mixture. In addition, a flow analysis of fluorescence intensity was performed for each sample, demonstrating that the BP- $C_{60}$  hybrid exhibited the strongest DCF fluorescence intensity (Fig. 3a and b), with the mean fluorescence intensity (MFI) value being approximately one order of magnitude higher than that of the BP/ $C_{60}$ -mixture (Fig. 3d). This result demonstrates that grafting of  $C_{60}$  molecules greatly enhanced the ROS production efficiency of the BP nanosheets within cells, consistent with the results of the photocatalytic degradation of dyes reported previously. Given that excessive oxidative stress of ROS can cause mitochondrial dysfunction in tumor cells,<sup>15</sup> we next compared the mitochondrial membrane potentials (MMPs) of different samples, as determined by the standard 1,1',3'-tetraethylimidacarbocyanine (JC-1) test. Normally, red JC-1 aggregates (JC-1-A) are able to accumulate in mitochondria. However, red JC-1-A is re-dispersed in the cytoplasm, and a green JC-1 monomer (JC-1-M) is generated, which enters the mitochondria when the MMP is reduced.<sup>32</sup> As shown in Fig. 3c, the BP- $C_{60}$



**Fig. 3** (a and c) ROS levels and MMP measured by DCF and JC-1 staining of 4T1 cells after co-incubation of the various groups with nanomaterials for 6 h: PBS+NIR,  $C_{60}$ -BM+NIR ( $30 \mu\text{g ml}^{-1}$ ,  $650 \text{ nm}$ ,  $0.5 \text{ W cm}^{-2}$ , 5 min), BP-BM+NIR groups ( $70 \mu\text{g ml}^{-1}$ ,  $650 \text{ nm}$ ,  $0.5 \text{ W cm}^{-2}$ , 5 min), BP/ $C_{60}$ -mixture groups ( $70 \mu\text{g ml}^{-1}$  BP and  $30 \mu\text{g ml}^{-1}$   $C_{60}$ ,  $650 \text{ nm}$ ,  $0.5 \text{ W cm}^{-2}$ , 5 min) and BP- $C_{60}$  ( $70 \mu\text{g ml}^{-1}$  BP and  $30 \mu\text{g ml}^{-1}$   $C_{60}$ ,  $650 \text{ nm}$ ,  $0.5 \text{ W cm}^{-2}$ , 5 min) respectively. (b) Flow cytometric analysis and DCF fluorescence intensity of the staining displayed in Fig. 2a. (d) Corresponding main fluorescence intensity (MFI) values displayed in Fig. 2b.

hybrid shows the greatest JC-1-M ratio, indicating that the BP- $C_{60}$  hybrid exhibited the greatest ability to disrupt mitochondrial function. It is worth noting that the laser power used in the *in vitro* experiments ( $0.5 \text{ W cm}^{-2}$ ) was lower than those typically reported in the literature regarding PDT application of BP.<sup>16,33,34</sup> Therefore, grafting of  $C_{60}$  molecules promoted generation of ROS at a relatively low power, benefitting *in vivo* PDT application of BP nanosheets. To the best of our knowledge, promoting ROS generation of BP *via* hybridization of fullerenes has not been widely reported; thus the BP- $C_{60}$  hybrid represents the first BP-fullerene hybrid nanomaterial fulfilling promoted ROS generation.

### *In vitro* photodynamic therapy

The high-efficiency ROS generation stimulates us to further explore the ability of the BP- $C_{60}$  hybrid to kill cancer cells *in vitro*. We first investigate the toxicity of the BP- $C_{60}$  hybrid to 4T1 cells under light and dark conditions, using the Cell Counting Kit-8 (CCK-8) assay (Fig. 4a and b). Since the content of BP in the BP- $C_{60}$  hybrid is about 70% (w/w),<sup>26</sup> the BP concentration gradients were set as 0, 70, and  $140 \mu\text{g ml}^{-1}$  for the PDT experiments. As shown in Fig. 4a, the cell survival rate decreased with the increase of the BP- $C_{60}$  hybrid concentration under near-infrared (NIR) light irradiation for all the samples, while the cell growth inhibition ratio reached approximately 90% ( $P < 0.001$ ) relative to that of the control PBS sample for the BP- $C_{60}$  hybrid, which is much higher than that for BP-BM (30%) and the BP/ $C_{60}$ -mixture ( $\sim 50\%$ ). Such an *in vitro* cytotoxicity of the BP- $C_{60}$  hybrid is also much higher than those for BP nanosheets including BP quantum dots reported in the literature.<sup>15</sup> The superior tumor killing ability of the BP- $C_{60}$  hybrid is due to its superior ability to generate ROS under light irradiation as discussed above. In the absence of light, the cell viability exceeded 90% even at a concentration of  $140 \mu\text{g ml}^{-1}$  for all the






Fig. 4 *In vitro* antitumor efficacy. (a) *In vitro* cytotoxicity of the different nanomaterials against 4T1 cells when exposed to light irradiation (650 nm, 0.5 W cm<sup>-2</sup>, 5 min). (b) *In vitro* cytotoxicity of the different nanomaterials against 4T1 cells in the absence of light irradiation (Dark). (c) *In vitro* cytotoxicity of the BP-C<sub>60</sub> hybrid against different cells in the absence of light irradiation. For consistency, the concentration of BP within BP-BM, the BP/C<sub>60</sub>-mixture and the BP-C<sub>60</sub> hybrid remains consistent for each group. The average weight ratio of BP within the BP-C<sub>60</sub> hybrid is estimated to be ~70% based on our previous study;<sup>26</sup> accordingly the concentration of the BP-C<sub>60</sub> hybrid injected into the mice is 0, 100, and 200 μg ml<sup>-1</sup>. (d) Fluorescence images of 4T1 cells co-stained with FDA (live cells: green) and PI (dead cells: red) following the addition of different samples with irradiation (70 μg ml<sup>-1</sup> BP and 30 μg ml<sup>-1</sup> C<sub>60</sub>, 650 nm, 0.5 W cm<sup>-2</sup>, 5 min). Scale bar = 50 μm. \*\*\* *P* < 0.001.

samples, suggesting that the toxicities of these samples on tumor cells are quite low. These results are consistent with those previously reported.<sup>35,36</sup> We further tested the toxic effect of the BP-C<sub>60</sub> hybrid towards other tumor cells (MCF-7 and Huh-7) and normal cells (RAW 264.7 and U937), and found that, without light irradiation, all the cell types displayed viabilities of more than 90% even at a high concentration of 140 μg ml<sup>-1</sup> (Fig. 4c). Hence, we confirmed that the intrinsic toxicity of the BP-C<sub>60</sub> hybrid is negligible, which is beneficial for its *in vivo* PDT applications.

We next evaluated the efficacy of PDT based on the staining of living and dead cells using fluorescein diacetate (FDA) and propidium iodide (PI) (Fig. 4d). For the BP-C<sub>60</sub> hybrid, the number of viable cells decreased drastically and a large number of apoptotic cells emitting red fluorescence appeared under illumination. In contrast, a large number of living cells (green) appeared in the PBS control and, compared with those for the BP-C<sub>60</sub> hybrid, fewer apoptotic cells appeared for other groups (BP-BM, C<sub>60</sub>-BM and BP/C<sub>60</sub>-mixture), indicating the limited therapeutic effect of these groups. These results show that grafting of C<sub>60</sub> molecules greatly improves the *in vitro* photodynamic anti-tumor efficacy of BP nanosheets.

### *In vivo* photodynamic therapy

The *in vivo* anti-tumor effect of the BP-C<sub>60</sub> hybrid was evaluated in a 4T1 mouse model. It has been reported that BP-based hybrid materials with a lateral size of about 200 nm and thickness of about 5.5 nm can be endocytosed into cells *via* micropinocytosis.<sup>33,36</sup> Since the BP-C<sub>60</sub> hybrid has an even smaller lateral

size and thickness as discussed above, it can be endocytosed into cells (see Fig. 1b). We first injected the samples directly into the tumor for PDT measurements and studied the therapeutic effect of intravenous injection of different concentrations of the BP-C<sub>60</sub> hybrid. The changes in tumor volume, which reflect the therapeutic effect of the BP-C<sub>60</sub> hybrid, were monitored for 14 days (Fig. 5a and d). In addition, we monitored the whole body weight every 2 days (Fig. 5b and e). According to the changes in the tumor volume, the BP-C<sub>60</sub> hybrid had the highest tumor inhibition rate (88.2%), which was much higher than those for C<sub>60</sub>-BM (30.7%), BP-BM (36.6%) and the BP/C<sub>60</sub> mixture (55.2%). The BP-C<sub>60</sub> hybrid displayed the best therapeutic effect due to its highest efficiency in generating ROS and its highest stability as discussed above. Moreover, even after injecting the BP-C<sub>60</sub> hybrid into the tail vein, the BP-C<sub>60</sub> hybrid still showed a considerable anti-tumor effect. At a concentration of 70 and 140 μg ml<sup>-1</sup>, the tumor inhibition rate was 35.9% and 65.6%, respectively, indicating that the anti-tumor activity of the BP-C<sub>60</sub> hybrid was concentration dependent. There was no obvious body weight loss during treatment, suggesting a good biocompatibility of the BP-C<sub>60</sub> hybrid. At the end of the 14 day experiment, the mice were sacrificed, the final tumor weight was obtained (Fig. 5c and f), and the tumor tissue was used for histological examination (Fig. 5i and j). According to the hematoxylin and eosin (HE) staining, the BP-C<sub>60</sub> hybrid, BP-BM, C<sub>60</sub>-BM, and BP/C<sub>60</sub>-mixture all caused structural deformations to different degrees or cell death compared to the




Fig. 5 *In vivo* antitumor efficacy. (a) Tumor volume over time, (b) change in the body weight over time and (c) mean tumor weight in different groups during the intratumoral injection treatment period. (d) Tumor volume over time, (e) change in body weight over time and (f) mean tumor weight in the different groups during the intravenous injection treatment period. (g) Mice and tumors in the different groups on day 14 following intratumoral injection. (h) Mice and tumors in the different groups on day 14 following intravenous injection. (i) HE, Ki-67 and TUNEL staining of cancer tissue from sacrificed mice exposed to various treatments for 14 days following intratumoral injection. Scale bar = 50 μm. (j) HE, Ki-67 and TUNEL staining of cancer tissue from sacrificed mice exposed to various treatments for 14 days following intravenous injection. Scale bar = 50 μm. Data represent means ± SEM (*n* = 5). \*\*\* *P* < 0.001.



PBS control, while the tumors from the BP-C<sub>60</sub> hybrid group exhibited the most obvious nuclear contraction or disappearance.<sup>37</sup> In addition, following treatment with the BP-C<sub>60</sub> hybrid, the proportion of Ki-67 positive cells was significantly lower than that for the control groups, indicating that the cell proliferation ability of tumor cells was significantly inhibited using the BP-C<sub>60</sub> hybrid.<sup>38</sup> In addition, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay slices were tested in the mice treated with the BP-C<sub>60</sub> hybrid, revealing that many tumor cells were dead or apoptotic as determined by green fluorescence staining.<sup>39</sup> In the tail vein injection experiment, the BP-C<sub>60</sub> hybrid with the highest concentration (containing 140 μg ml<sup>-1</sup> BP) exhibited superior anti-tumor ability to the PBS group and the group with the lower concentration (containing 70 μg ml<sup>-1</sup> BP). With the increase of the sample concentration, more apoptosis and less proliferation of cancer cells were observed, indicating that the therapeutic effect was concentration-dependent. Together, these histological results reveal that the BP-C<sub>60</sub> hybrid has the best anti-tumor effects compared with BP-BM or C<sub>60</sub>-BM.

Assessment of systemic toxicity is another important aspect of determining biomedical material safety.<sup>40</sup> We used histopathology to evaluate the *in vivo* toxicity of the BP-C<sub>60</sub> hybrid. As shown in ESI Fig. S5,† after intravenous injection of the BP-C<sub>60</sub> hybrid at different concentrations, the main organs of the mice showed no obvious damage, confirming the good biocompatibility and low systemic toxicity of the BP-C<sub>60</sub> hybrid. Although it has been reported that BP is intrinsically toxic being able to kill tumor cells, at our used doses (70 or 140 μg ml<sup>-1</sup>) BP has low systemic toxicity, proving its biomedical applications.

### Mechanism of enhancement of the photodynamic therapy efficacy of BP

The significantly enhanced PDT efficacy of BP nanosheets after grafting C<sub>60</sub> molecules can be explained by considering the change in the energy band structure. The conduction band (CB) and valence band (VB) energy levels of the BP-C<sub>60</sub> hybrid determined by synchrotron radiation photoemission spectroscopy (SRPES) are -3.27 eV and -4.64 eV *versus* vacuum level (-1.23 and 0.14 eV *vs.* the reversible hydrogen electrode (RHE), respectively), which are both shifted negatively relative to those of pristine BP-BM.<sup>26</sup> In particular, the negative shift of the CB level facilitates the reduction of the dissolved O<sub>2</sub> to generate <sup>•</sup>O<sub>2</sub><sup>-</sup>, which then transforms to <sup>•</sup>OH radicals which consequently act as ROS to kill the tumor cells (see ESI Fig. S6†). Since grafting of C<sub>60</sub> molecules promotes generation of ROS of BP as discussed above, significantly enhanced PDT efficacy is achieved by the BP-C<sub>60</sub> hybrid.

## Conclusions

In summary, the BP-C<sub>60</sub> hybrid material, in which C<sub>60</sub> was covalently grafted onto the edge of BP nanosheets, was applied as a novel endocytosed photosensitizer for PDT applications. Owing to the high stability of hydrophobic C<sub>60</sub> against light, oxygen and water, grafting of stable C<sub>60</sub> molecules onto the edges of BP nanosheets resulted in dramatic improvement of

the physiological stability of BP nanosheets in serum, PBS and water. Furthermore, grafting of C<sub>60</sub> molecules greatly promoted the ROS production efficiency of BP nanosheets within cells. Consequently the *in vitro* cell growth inhibition ratio reaches approximately 90% relative to that of the blank PBS sample for the BP-C<sub>60</sub> hybrid. According to the *in vivo* anti-tumor measurements, the BP-C<sub>60</sub> hybrid has the highest tumor inhibition rate of 88.2%, which is much higher than that of unmodified BP-BM (36.6%). After injection of the BP-C<sub>60</sub> hybrid at a relatively high concentration of 70 or 140 μg ml<sup>-1</sup> into the tail vein of mice, a tumor inhibition rate of 65.6% was achieved. The *in vivo* toxicity of the BP-C<sub>60</sub> hybrid was further evaluated by using histopathology, confirming its low systemic toxicity. The significantly enhanced PDT efficacy achieved by the BP-C<sub>60</sub> hybrid is attributed to the promoted generation of <sup>•</sup>OH radicals through photoinduced electron transfer from BP to C<sub>60</sub>, which act as ROS to kill tumor cells. As the first BP-fullerene hybrid nanomaterial fulfilling promoted ROS generation and consequently enhanced PDT efficacy, our strategy in enhancing the PDT efficacy of BP nanosheets paves the way for the application of BP in tumor therapies.

## Experimental

### Materials

Black phosphorus (BP) crystals were purchased from XFNANO (Nanjing, China). C<sub>60</sub> (99.6%) was acquired from FUNANO (Xiamen, China). Isopropanol (IPA) and absolute ethanol were obtained from Sinopharm Chemical Reagent Co. Ltd (Shanghai, China). All the chemicals were used directly without further purification. *p*-Phthalic acid (PTA) was purchased from ShangHai YuanYe Biotechnology (Shanghai, China). Rhodamine B (technical grade) was obtained from INNOCHEM (Beijing, China). PBS and fetal bovine serum (FBS) were acquired from Thermo-Fisher (USA). Fluorescein diacetate (FDA), propidium iodide (PI) and cell counting kit-8 (CCK-8) assays were purchased from Sigma-Aldrich (USA). DCFH-DA and JC-1 were obtained from Beyotime Company (China).

### Synthesis of the BP-C<sub>60</sub> hybrid

The BP-C<sub>60</sub> hybrid was prepared by a solid-state mechanochemical method, as reported previously.<sup>26</sup> Briefly, 50 g of 3 mm diameter ZrO<sub>2</sub> balls were placed in a ZrO<sub>2</sub> ball-milling jar, and then 300 mg bulk BP and 600 mg C<sub>60</sub> powders were added. The jar was sealed in an argon-filled glovebox and ball-milling was performed for 24 h, as reported previously. The rotation speed was 250 rpm, and the ball-milling procedure was also performed for 30 min milling time with a 15 min interval to cool the instrument. Finally, unreacted C<sub>60</sub> was removed from the milled product by Soxhlet-extraction using CS<sub>2</sub> for 48 h, followed by drying for 24 h at 40 °C in a vacuum.

### Cell culture

The Huh-7 human liver cancer cell line, U937 human macrophage cell line, RAW 264.7 mouse macrophage cell line, MCF-7 human breast cancer cell lines and 4T1 mouse breast cancer cell



line cells were obtained from the Cell Bank of the Chinese Academy of Sciences and incubated in RPMI-1640 medium supplemented with 10% FBS in a humidified atmosphere containing 5% CO<sub>2</sub> at 37 °C.

Animal models: female BALB/c mice aged 4–5 weeks were purchased from the Vital River Company (Beijing, China). A total of  $1 \times 10^6$  4T1 cells suspended in 100  $\mu$ l PBS were injected subcutaneously into each mouse to establish tumor models. All the protocols were approved by the Wuhan University Animal Care Facility and National Institutes of Health Guidelines.

### Intracellular reactive oxygen species (ROS) generation

For determination of ROS levels *via* fluorescence imaging, 4T1 cells were incubated for 6 h in five different groups of samples, as follows: (1) control (PBS), (2) C<sub>60</sub>-BM, (3) BP-BM, (4) BP/C<sub>60</sub>-mixture, and (5) BP-C<sub>60</sub>. BP was added at a concentration of 140  $\mu$ g ml<sup>-1</sup> in groups 3, 4 and 5. The C<sub>60</sub> concentration was 60  $\mu$ g ml<sup>-1</sup> in groups 2, 4 and 5. The fluorescent dye DCFH-DA (10  $\mu$ mol L<sup>-1</sup>) was added and co-incubated for 20 min at 37 °C. The cells in each group were then irradiated with a 650 nm laser at a power density of 0.5 W cm<sup>-2</sup> for 5 min. ROS levels were measured using fluorescence microscopy (IX81, Olympus, Japan). The fluorescence intensity in each group was measured using a flow cytometer (FACScaliber, Becton Dickinson, USA). JC-1 assays were performed by incubating 4T1 cells for 6 h with five different groups of materials: (1) control (PBS), (2) C<sub>60</sub>-BM, (3) BP-BM, (4) BP/C<sub>60</sub>-mixture, and (5) BP-C<sub>60</sub>. The BP concentration was 140  $\mu$ g ml<sup>-1</sup> in groups 3, 4 and 5. The C<sub>60</sub> concentration was 60  $\mu$ g ml<sup>-1</sup> in groups 2, 4 and 5. The cells in each group were then irradiated with a 650 nm laser at a power density of 0.5 W cm<sup>-2</sup> for 5 min. The cells were stained with JC-1 for 30 min prior to washing with PBS. Mitochondrial damage or disruption was then evaluated by fluorescence microscopy (IX81, Olympus, Japan).

### *In vitro* phototoxicity

Phototoxicity was evaluated using a CCK-8 assay, performed in 96-well plates in which 4T1 cells were incubated at a density of  $5 \times 10^3$  cells per well. Five different samples were compared: (1) control (PBS), (2) C<sub>60</sub>-BM, (3) BP-BM, (4) BP/C<sub>60</sub>-mixture, and (5) BP-C<sub>60</sub>. The concentration of BP was 70  $\mu$ g ml<sup>-1</sup> in groups 3, 4 and 5, and the C<sub>60</sub> powder concentration was 30  $\mu$ g ml<sup>-1</sup> in groups 2, 4 and 5. The 4T1 cells were incubated for 6 h and then irradiated for 5 min at a power density of 0.5 W cm<sup>-2</sup> using a 650 nm laser. CCK-8 at a concentration of 5 mg ml<sup>-1</sup> in PBS was added to the plates and then incubated for further 4 h, after which the absorbance at 450 nm was measured using a microplate reader. Background absorption of each well was subtracted from individual measurements. The final phototoxicity of the samples was calculated using:  $(T/C \times 100\%)$ , in which  $T$  represents the optical density value of the treatment group and  $C$  represents the optical density value of the control group. Phototoxicity of the different groups was analyzed at different concentrations, including 0 and 140  $\mu$ g ml<sup>-1</sup> BP.

In addition, the phototoxicity of each sample was investigated further. 4T1 cells were seeded in the wells of 96-well plates

and incubated overnight. The culture medium was refreshed and then a sample of each of the five groups was added to the cells, the groups comprising: (1) control (PBS), (2) C<sub>60</sub>-BM, (3) BP-BM, (4) BP/C<sub>60</sub>-mixture, and (5) BP-C<sub>60</sub>. The cells in contact with the different samples were then irradiated with a 650 nm laser for 5 min after incubation for 4 h at a power density of 0.5 W cm<sup>-2</sup>. After 24 h, the cells in the various groups were washed with PBS then incubated with FDA and PI. Finally, the cells were observed using a fluorescence microscope (IX81, Olympus, Japan).

### *In vitro* dark toxicity

The toxicity of the various nanomaterials to tumor cells was evaluated in the absence of light using a CCK-8 assay. 4T1 cells were seeded in the wells of 96-well plates at a density of  $5 \times 10^3$  cells per well, and then incubated for 24 h, consistent with the *in vitro* phototoxicity analysis described above. No laser irradiation was performed on the samples. Instead, the toxicity of the BP-C<sub>60</sub> hybrid material was evaluated in Huh-7 human liver cancer cells, U937 human macrophages, RAW 264.7 mouse macrophages, and MCF-7 human breast cancer cells in the dark.

### *In vivo* anti-tumor study

Because C<sub>60</sub> is hydrophobic, we initially injected the nanomaterial directly into the tumor to perform photodynamic therapy (intratumoral injection group). The therapeutic effect of the BP-C<sub>60</sub> hybrid materials at different concentrations was assessed by injection through the tail vein of mice (tail vein injection group). Female BALB/c mice aged 4–5 weeks were purchased from the Vital River Company (Beijing, China). A total of  $1 \times 10^6$  4T1 cells in suspension in 100  $\mu$ l PBS were subcutaneously injected into each mouse in order to establish the tumor model. The mice were randomly divided into 5 groups, each group comprising 5 mice in order to increase the statistical power of the study. Control PBS and the different nanomaterials as described above, were injected intratumorally, as appropriate for each group. The concentration of BP in groups 3, 4 and 5 was 140  $\mu$ g ml<sup>-1</sup>, with a concentration of C<sub>60</sub> of 60  $\mu$ g ml<sup>-1</sup>. The tumors in the mice were irradiated using a 650 nm laser for 30 min following injection (0.5 W cm<sup>-2</sup>, 10 min). This step was performed every 2 days for 14 days. When the tumors had increased to a volume of 200 mm<sup>3</sup>, the mice were randomly divided into three groups, each group comprising 5 mice, consisting of: (1) control (PBS), (2) BP-C<sub>60</sub> containing 70  $\mu$ g ml<sup>-1</sup> BP and (3) BP-C<sub>60</sub> containing 140  $\mu$ g ml<sup>-1</sup> BP. The tumor site of all the groups was irradiated for 10 min using a 650 nm laser 24 h post-injection at a power density of 0.5 W cm<sup>-2</sup>. This was also conducted every 2 days for 14 days, during which time the tumor volume and body weight of each mouse were also measured. All the mice were subsequently sacrificed after 14 days and the five major organs, including the heart, liver, spleen, lungs and kidneys from each group were collected and washed with PBS. The organs were then fixed with paraformaldehyde for further histological analysis. The tumor tissue was then weighed, fixed in 4% neutral buffered formalin,



placed in paraffin and ultimately sectioned to a thickness of 4  $\mu\text{m}$ . Finally, the tissues were stained and examined by optical microscopy.

### Statistical analysis

Statistical analysis was performed using a one-way analysis of variance (ANOVA) followed by a post-hoc Tukey comparison test, using GraphPad Prism 5.0 software. A *P*-value of  $< 0.05$  was considered statistically significant.

### Measurements and characterization

UV-vis absorption spectroscopy was performed on a 3700 UV-vis spectrometer (Shimadzu, Japan). FTIR spectra were obtained on a TENSOR 27 spectrometer (Bruker, Germany) at room temperature. Raman spectra were obtained using inVia Raman Microscope equipment (Renishaw, England) with a 532 nm excitation laser. Scanning electron microscopy (SEM) images were obtained from a JEOL JSM-6390LA instrument (Rigaku, Japan). The high-resolution transmission electron microscopy (HR-TEM) was performed on a JEOL-2010 (Rigaku, Japan) microscope operating at a voltage of 200 kV. Atomic force microscopy (AFM) measurements were conducted on an XE7 scanning probe microscope (Park, Korea).

Synchrotron radiation photoemission spectroscopy (SR-PES) experiments were performed at the Catalysis and Surface Science endstation in the National Synchrotron Radiation Laboratory (NSRL), Hefei, China, measured using synchrotron radiation light as the excitation source with a photon energy of 39.9 eV. A sample bias of  $-5$  V was applied to observe the secondary electron cutoff. The powdery materials were fixed on the substrate with conductive adhesive and then loaded into the cavity and evacuated overnight for testing.

### Conflicts of interest

There are no conflicts to declare.

### Acknowledgements

This work was partially supported by the National Key Research and Development Program of China (2017YFA0402800 and 2018YFC1311300) and National Natural Science Foundation of China (No. U1932214, 51925206, and U1604175).

### Notes and references

- 1 C. Minelli, S. B. Lowe and M. M. Stevens, *Small*, 2010, **6**, 2336–2357.
- 2 D. E. Dolmans, D. Fukumura and R. K. Jain, *Nat. Rev. Cancer*, 2003, **3**, 380–387.
- 3 X. S. Li, S. Lee and J. Yoon, *Chem. Soc. Rev.*, 2018, **47**, 1174–1188.
- 4 H. Abrahamse and M. R. Hamblin, *Biochem. J.*, 2016, **473**, 347–364.
- 5 R. C. Lv, D. Yang, P. P. Yang, J. T. Xu, F. He, S. L. Gai, C. X. Li, Y. L. Dai, G. X. Yang and J. Lin, *Chem. Mater.*, 2016, **28**, 4724–4734.
- 6 A. J. Mannix, B. Kiraly, M. C. Hersam and N. P. Guisinger, *Nat. Rev. Chem.*, 2017, **1**, 0014.
- 7 L. K. Li, Y. J. Yu, G. J. Ye, Q. Q. Ge, X. D. Ou, H. Wu, D. L. Feng, X. H. Chen and Y. B. Zhang, *Nat. Nanotechnol.*, 2014, **9**, 372–377.
- 8 L. Z. Kou, C. F. Chen and S. C. Smith, *J. Phys. Chem. Lett.*, 2015, **6**, 2794–2805.
- 9 S. H. Liu, S. H. Lin, P. You, C. Surya, S. P. Lau and F. Yan, *Angew. Chem., Int. Ed.*, 2017, **56**, 13717–13721.
- 10 J. R. Choi, K. W. Yong, J. Y. Choi, A. Nilghaz, Y. Lin, J. Xu and X. N. Lu, *Theranostics*, 2018, **8**, 1005–1026.
- 11 S. Anju, J. Ashtami and P. V. Mohanan, *Mater. Sci. Eng., C*, 2019, **97**, 978–993.
- 12 H. Y. Wang and X. F. Yu, *Small*, 2018, **14**, 1702830.
- 13 H. Wang, X. Z. Yang, W. Shao, S. C. Chen, J. F. Xie, X. D. Zhang, J. Wang and Y. Xie, *J. Am. Chem. Soc.*, 2015, **137**, 11376–11382.
- 14 Y. Liu, S. Yu, P. Yang and B. Hu, *Mater. Sci. Technol.*, 2019, 1–11.
- 15 T. Guo, Y. Wu, Y. Lin, X. Xu, H. Lian, G. M. Huang, J. Z. Liu, X. P. Wu and H. H. Yang, *Small*, 2018, **14**, 1702815.
- 16 J. T. Liu, T. R. Liu, P. Du, L. Zhang and J. P. Lei, *Angew. Chem., Int. Ed.*, 2019, **58**, 7808–7812.
- 17 S. Kuriakose, T. Ahmed, S. Balendhran, V. Bansal, S. Sriram, M. Bhaskaran and S. Walia, *2D Mater.*, 2018, **5**, 032001.
- 18 Y. Abate, D. Akinwande, S. Gamage, H. Wang, M. Snure, N. Poudel and S. B. Cronin, *Adv. Mater.*, 2018, **30**, 1704749.
- 19 Z. H. Hu, Q. Li, B. Lei, Q. H. Zhou, D. Xiang, Z. Y. Lyu, F. Hu, J. Y. Wang, Y. J. Ren, R. Guo, E. Goki, L. Wang, C. Han, J. L. Wang and W. Chen, *Angew. Chem., Int. Ed.*, 2017, **56**, 9131–9135.
- 20 C. R. Ryder, J. D. Wood, S. A. Wells, Y. Yang, D. Jariwala, T. J. Marks, G. C. Schatz and M. C. Hersam, *Nat. Chem.*, 2016, **8**, 597–602.
- 21 Y. J. Liu, P. F. Gao, T. M. Zhang, X. J. Zhun, M. M. Zhang, M. Q. Chen, P. W. Du, G. W. Wang, H. X. Ji, J. L. Yang and S. F. Yang, *Angew. Chem., Int. Ed.*, 2019, **58**, 1479–1483.
- 22 L. Wu, J. H. Wang, J. Lu, D. N. Liu, N. Yang, H. Huang, P. K. Chu and X.-F. Yu, *Small*, 2018, **14**, 1801405.
- 23 Y. H. Zhao, Q. H. Zhou, Q. Li, X. J. Yao and J. L. Wang, *Adv. Mater.*, 2017, **29**, 1603990.
- 24 Q. L. Feng, H. Y. Liu, M. J. Zhu, J. Shang, D. Liu, X. Q. Cui, D. Q. Shen, L. Z. Kou, D. Mao, J. B. Zheng, C. Li, J. Zhang, H. Xu and J. L. Zhao, *ACS Appl. Mater. Interfaces*, 2018, **10**, 9679–9687.
- 25 K. L. Kuntz, R. A. Wells, J. Hu, T. Yang, B. J. Dong, H. H. Guo, A. H. Woome, D. L. Druffel, A. Alabanza, D. Tománek and S. C. Warren, *ACS Appl. Mater. Interfaces*, 2017, **9**, 9126–9135.
- 26 X. J. Zhu, T. M. Zhang, D. C. Jiang, H. L. Duan, Z. J. Sun, M. M. Zhang, H. C. Jin, R. N. Guan, Y. J. Liu, M. Q. Chen, H. X. Ji, P. W. Du, W. S. Yan, S. Q. Wei, Y. L. Lu and S. F. Yang, *Nat. Commun.*, 2018, **9**, 4177.



- 27 P. Mroz, G. P. Tegos, H. Gali, T. Wharton, T. Sarna and M. R. Hamblin, *Photochem. Photobiol. Sci.*, 2007, **6**, 1139–1149.
- 28 T. S. Wang and C. R. Wang, *Small*, 2019, 1901522.
- 29 I. Y. Jeon, H. J. Choi, S. M. Jung, J. M. Seo, M. J. Kim, L. M. Dai and J. B. Baek, *J. Am. Chem. Soc.*, 2013, **135**, 1386–1393.
- 30 S. E. Zhu, F. Li and G. W. Wang, *Chem. Soc. Rev.*, 2013, **42**, 7535–7570.
- 31 B. Chai, X. Liao, F. K. Song and H. Zhou, *Dalton Trans.*, 2014, **43**, 982–989.
- 32 S. H. Wang, L. Shang, L. L. Li, Y. J. Yu, C. W. Chi, K. Wang, J. Zhang, R. Shi, H. Y. Shen, G. I. Waterhouse, S. J. Liu, J. Tian, T. R. Zhang and H. Y. Liu, *Adv. Mater.*, 2016, **28**, 8379–8387.
- 33 X. Y. Yang, D. Y. Wang, Y. H. Shi, J. H. Zou, Q. Zhao, Q. Zhang, W. Huang, J. J. Shao, X. J. Xie and X. C. Dong, *ACS Appl. Mater. Interfaces*, 2018, **10**, 12431–12440.
- 34 R. Jain, Y. Singh, S. Cho, S. P. Sasikala, S. H. Koo, R. Narayan, H. Jung, Y. Jung and S. O. Kim, *Chem. Mater.*, 2019, **31**, 2786–2794.
- 35 X. W. Zeng, M. M. Luo, G. Liu, X. S. Wang, W. Tao, Y. X. Lin, X. Y. Ji, L. Nie and L. Mei, *Adv. Sci.*, 2018, **5**, 1800510.
- 36 W. S. Chen, J. Ouyang, H. Liu, M. Chen, K. Zeng, J. P. Sheng, Z. J. Liu, Y. J. Han, L. Q. Wang, J. Li, L. Deng, Y. N. Liu and S. J. Guo, *Adv. Mater.*, 2017, **29**, 1603864.
- 37 L. L. Bu, Z. L. Zhao, J. F. Liu, S. R. Ma, C. F. Huang, B. Liu, W. F. Zhang and Z. J. Sun, *Oncotarget*, 2015, **6**, 41944–41958.
- 38 G. T. Yu, L. L. Bu, Y. Y. Zhao, B. Liu, W. F. Zhang, Y. F. Zhao, L. Zhang and Z. J. Sun, *Am. J. Cancer Res.*, 2014, **4**, 764–775.
- 39 M. Q. Chu, Y. X. Shao, J. L. Peng, X. Y. Dai, H. K. Li, Q. S. Wu and D. L. Shi, *Biomaterials*, 2013, **34**, 4078–4088.
- 40 A. Nel, T. Xia, L. Madler and N. Li, *Science*, 2006, **311**, 622–627.

